Mucosal Vaccination by Adenoviruses Displaying Reovirus Sigma 1

Authors

Eric A. Weaver, University of Nebraska-LincolnFollow
Zenaido T. Camacho, Western New Mexico University, Silver City
Matthew L. Hillestad, Mayo Clinic, Rochester
Catherine M. Crosby, Mayo Clinic, Rochester
Mallory A. Turner, Mayo Clinic, Rochester
Adam J. Guenzel, Mayo Clinic, Rochester
Hind J. Fadel, Mayo Clinic, Rochester
George T. Mercier, University of Houston, Houston
Michael A. Barry, Mayo ClinicFollow

Document Type

Article

Date of this Version

8-1-2016

Citation

2015 Published by Elsevier Inc.

doi:10.1016/j.virol.2015.02.050

Comments

Virology. 2015 August ; 482: 60–66.

Abstract

We previously developed adenovirus serotype 5 (Ad5) vectors displaying the sigma 1 protein from reovirus as mucosal vaccines. Ad5-sigma retargets to JAM-1 and sialic acid, but had 40-fold reduced gene delivery when compared to Ad5. While weaker at transduction, Ad5-sigma generated stronger T cell responses than Ad5 when used for mucosal immunization. New Ad5-fiber-sigma vectors were generated here by varying the number of fiber β-spiral shaft repeats (R) fused between fiber tail and the sigma. Ad5 virions encoding R3, R14, and R20 chimeras were rescued. Increasing chimera length led to their decreasing encapsidation of these proteins in the virions. Ad5-R3 and R14 mediated JAM-1- retargeting in vitro. When used to immunize mice by the intranasal route, Ad5-R3-sigma produced similar luciferase activity to Ad5, but higher serum and vaginal antibody responses. These data suggest optimized Ad-Sigma vectors may be useful vectors for mucosal vaccination.